TNF and Behcet disease: Currently, the monoclonal antibodies anti-TNF-α IFX [78] and adalimumab (ADA) [79] along with the human TNF receptor p75 Fc fusion protein etanercept (ETN) [80] have been advocated for the treatment of different BD manifestations.